119 related articles for article (PubMed ID: 38016328)
1. Lead to hit ruthenium-cyclopentadienyl anticancer compounds: Cytotoxicity against breast cancer cells, metabolic stability and metabolite profiling.
Maximiano I; Henriques C; Teixeira RG; Marques F; Valente A; Antunes AMM
J Inorg Biochem; 2024 Feb; 251():112436. PubMed ID: 38016328
[TBL] [Abstract][Full Text] [Related]
2. Novel "ruthenium cyclopentadienyl"-peptide conjugate complexes against human FGFR(+) breast cancer.
Franco Machado J; Machuqueiro M; Marques F; Robalo MP; Piedade MFM; Garcia MH; Correia JDG; Morais TS
Dalton Trans; 2020 May; 49(18):5974-5987. PubMed ID: 32314752
[TBL] [Abstract][Full Text] [Related]
3. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
[TBL] [Abstract][Full Text] [Related]
4. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
5. Novel family of [RuCp(N,N)(P)]
Teixeira RG; Mészáros JP; Matos B; Côrte-Real L; Xavier CPR; Fontrodona X; Garcia MH; Romero I; Spengler G; Vasconcelos MH; Tomaz AI; Enyedy ÉA; Valente A
Eur J Med Chem; 2023 Dec; 262():115922. PubMed ID: 37944388
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium(II)-Arene Thiocarboxylates: Identification of a Stable Dimer Selectively Cytotoxic to Invasive Breast Cancer Cells.
Stephens LJ; Levina A; Trinh I; Blair VL; Werrett MV; Lay PA; Andrews PC
Chembiochem; 2020 Apr; 21(8):1188-1200. PubMed ID: 31701616
[TBL] [Abstract][Full Text] [Related]
7. Fighting Multidrug Resistance with Ruthenium-Cyclopentadienyl Compounds: Unveiling the Mechanism of P-gp Inhibition.
Teixeira RG; Salaroglio IC; Oliveira NFB; Sequeira JGN; Fontrodona X; Romero I; Machuqueiro M; Tomaz AI; Garcia MH; Riganti C; Valente A
J Med Chem; 2023 Oct; 66(20):14080-14094. PubMed ID: 37616241
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the In Vitro and In Vivo Efficacy of Ruthenium Polypyridyl Compounds against Breast Cancer.
Lenis-Rojas OA; Roma-Rodrigues C; Fernandes AR; Carvalho A; Cordeiro S; Guerra-Varela J; Sánchez L; Vázquez-García D; López-Torres M; Fernández A; Fernández JJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445620
[TBL] [Abstract][Full Text] [Related]
9. Effect of
Mukherjee A; Acharya S; Purkait K; Chakraborty K; Bhattacharjee A; Mukherjee A
Inorg Chem; 2020 May; 59(9):6581-6594. PubMed ID: 32295347
[TBL] [Abstract][Full Text] [Related]
10. Unprecedented inhibition of P-gp activity by a novel ruthenium-cyclopentadienyl compound bearing a bipyridine-biotin ligand.
Côrte-Real L; Karas B; Gírio P; Moreno A; Avecilla F; Marques F; Buckley BT; Cooper KR; Doherty C; Falson P; Garcia MH; Valente A
Eur J Med Chem; 2019 Feb; 163():853-863. PubMed ID: 30579125
[TBL] [Abstract][Full Text] [Related]
11. Lapachol in the Design of a New Ruthenium(II)-Diphosphine Complex as a Promising Anticancer Metallodrug.
Oliveira KM; Honorato J; Demidoff FC; Schultz MS; Netto CD; Cominetti MR; Correa RS; Batista AA
J Inorg Biochem; 2021 Jan; 214():111289. PubMed ID: 33137682
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium-Cyclopentadienyl Bipyridine-Biotin Based Compounds: Synthesis and Biological Effect.
Côrte-Real L; Karas B; Brás AR; Pilon A; Avecilla F; Marques F; Preto A; Buckley BT; Cooper KR; Doherty C; Garcia MH; Valente A
Inorg Chem; 2019 Jul; 58(14):9135-9149. PubMed ID: 31241925
[TBL] [Abstract][Full Text] [Related]
13. Polymer "ruthenium-cyclopentadienyl" conjugates - New emerging anti-cancer drugs.
Moreira T; Francisco R; Comsa E; Duban-Deweer S; Labas V; Teixeira-Gomes AP; Combes-Soia L; Marques F; Matos A; Favrelle A; Rousseau C; Zinck P; Falson P; Garcia MH; Preto A; Valente A
Eur J Med Chem; 2019 Apr; 168():373-384. PubMed ID: 30826512
[TBL] [Abstract][Full Text] [Related]
14. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
15. "Half-Sandwich" Ruthenium Complexes with Alizarin as Anticancer Agents:
de Araujo-Neto JH; Guedes APM; Leite CM; Moraes CAF; Santos AL; Brito RDS; Rocha TL; Mello-Andrade F; Ellena J; Batista AA
Inorg Chem; 2023 May; 62(18):6955-6969. PubMed ID: 37099760
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium(II)-Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs.
Teixeira-Guedes C; Brás AR; Teixeira RG; Valente A; Preto A
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745864
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
18. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets.
Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA
Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850
[TBL] [Abstract][Full Text] [Related]
19. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
20. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
